| Literature DB >> 35893561 |
Mousa Alreshidi1,2, Hugh Dunstan3, Tim Roberts4, Fevzi Bardakci1, Riadh Badraoui1,5, Mohd Adnan1, Mohd Saeed1, Fayez Alreshidi6, Yazeed Albulaihed1, Mejdi Snoussi1,7.
Abstract
The sharp increase in infections due to Staphylococcus aureus is associated with its ability to adapt to changes in its habitat. This study aimed to investigate the differences in the cytoplasmic amino acid profiles of a clinical strain of S. aureus under five combinations of stress-induced conditions representative of a wound site by varying temperature 35-37 °C, adding 0-5% NaCl and adjusting pH 6-8. The results indicated that aspartic acid, lysine, glutamic acid and histidine were the most abundant cytoplasmic amino acids in the control samples grown under optimal growth conditions. However, the magnitudes and levels of these amino acids were altered under the various wound site conditions, which led to differential cytoplasmic amino acid profiles as characterized by multivariate analyses (PLS-DA). The total cytoplasmic amino acid content was significantly reduced in the cells grown with 2.5% NaCl added at pH 7 and 37 °C relative to the control samples and other growth regimes. However, all combinations of enhanced stress conditions showed unique and characteristic changes in the concentration profiles of the cytoplasmic amino acids. These outcomes supported the hypothesis that bacterial cells of S. aureus maintain different metabolic homeostasis under various stress-induced conditions. The potent capability of S. aureus to constantly and rapidly acclimatize to variations within the environment may reflect the crucial feature supporting its virulence as an opportunistic pathogenic bacterium to invade the wound site. Understanding the control systems governing these marked changes in amino acids during the adaptation to the potential wound site conditions of this dangerous bacterium may offer new clinical controls to combat infection.Entities:
Keywords: Staphylococcus aureus; adaptation; amino acid metabolism
Year: 2022 PMID: 35893561 PMCID: PMC9331416 DOI: 10.3390/microorganisms10081503
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
The concentrations of S. aureus cytoplasmic amino acids following growth under differing experimental regimes. The concentration is expressed as nmol mg−1 dry cell weight (Mean + SD, p < 0.05).
| Amino Acid Names | Amino Acids | Control | Treatment 1 (2.5% NaCl, pH 7, 37 °C) | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 |
|---|---|---|---|---|---|---|---|
| Alanine | ALA | 3.38 ± 0.37 | 2.04 ± 0.15 | 7.96 ± 0.69 a | 5.45 ± 0.50 | 26.05 ± 4.35 a | 6.15 ± 0.40 |
| Glycine | GLY | 4.55 ±1.93 | 2.25 ± 1.64 | 1.44 ± 0.12 a | 3.74 ± 0.38 | 3.44 ± 0.96 | 2.23 ±0.71 |
| α-Aminobutyric acid | ABA | 0.20 ± 0.15 | 0.41 ± 0.42 | 0.37 ± 0.04 | 0.53 ± 0.08 | 0.14 ± 0.20 | 0.40 ± 0.04 |
| Valine | VAL | 6.46 ± 3.01 | 2.87 ± 0.28 a | 9.47 ± 0.46 a | 10.59 ± 0.50 a | 2.50 ± 0.54 a | 4.04 ± 0.44 |
| ß-Aminoisobutyric acid | BAIB | 1.62 ± 0.20 | 1.61 ± 0.25 | 0.84 ± 0.03 a | 0.72 ± 0.03 a | 0.00 ± 0.00 a | 0.74 ± 0.19 a |
| Leucine | LEU | 2.23 ± 1.19 | 1.24 ± 0.43 | 3.77 ± 0.41 a | 2.84 ± 0.25 | 0.42 ± 0.23 a | 2.52 ± 0.36 |
| Allo-Isoleucine | AILE | 0.25 ± 0.18 | 0.32 ± 0.05 | 0.58 ± 0.05 a | 0.94 ± 0.11 a | 0.00 ± 0.00 a | 0.47 ± 0.11 a |
| Isoleucine | ILE | 1.76 ± 1.03 | 0.68 ± 0.11 a | 3.41 ± 0.24 a | 3.08 ± 0.20 a | 0.63 ± 0.15 a | 0.76 ± 0.12 a |
| Serine | SER | 1.23 ± 0.30 | 3.02 ± 1.32 a | 0.64 ± 0.46 a | 0.86 ± 0.06 | 9.32 ± 3.28 a | 2.12 ± 0.20 |
| Proline | PRO | 10.83 ± 6.77 | 3.08 ± 0.55 a | 32.01 ± 2.99 a | 30.14 ± 2.30 a | 79.79 ± 17.70 a | 4.98 ± 1.01 a |
| Asparagine | ASN | 4.84 ± 0.97 | 4.59 ± 0.42 | 5.40 ± 0.13 | 4.87 ± 0.21 | 4.53 ± 1.64 | 7.72 ± 0.90 a |
| Aspartic acid | ASP | 180.4 ± 32.5 | 156.63 ± 29.33 | 124.78 ± 10.18 a | 102.24 ± 9.08 a | 55.51 ± 11.06 a | 158.01 ± 16.14 |
| Methionine | MET | 6.14 ± 1.83 | 2.31 ± 0.84 a | 10.36 ± 0.86 a | 9.38 ± 1.08 a | 2.63 ± 0.55 a | 2.43 ± 1.74 a |
| 4-Hydroxyproline | HYP | 0.47 ± 0.28 | 0.62 ± 0.98 | 0.00 ± 0.00 | 0.49 ± 0.04 | 3.12 ± 0.72 a | 1.07 ± 0.05 |
| Glutamic acid | GLU | 51.94 ±13.87 | 55.82 ± 9.98 | 110.07 ± 2.72 a | 116.94 ± 4.25 a | 95.62 ± 16.66 a | 152.76 ± 40.73 a |
| Phenylalanine | PHE | 3.26 ± 1.20 | 2.10 ± 0.14 | 3.01 ± 0.15 | 2.66 ± 0.17 | 0.99 ± 0.26 a | 1.51 ± 1.07 a |
| α-Aminoadipic acid | AAA | 3.31 ± 1.73 | 1.09 ± 0.43 a | 0.93 ± 0.05 a | 1.57 ± 0.08 a | 0.15 ± 0.21 a | 0.46 ± 0.07 a |
| Glutamine | GLN | 2.11 ± 2.73 | 0.67 ± 0.35 | 2.72 ± 2.30 | 3.28 ± 3.62 | 13.25 ± 3.39 a | 3.96 ± 1.55 |
| Ornithine | ORN | 5.53 ± 1.14 | 5.73 ± 0.58 | 5.47± 0.39 | 4.12 ± 0.13 | 6.58 ± 1.06 | 13.21 ± 0.91 a |
| Lysine | LYS | 67.22 ± 13.05 | 36.24 ± 17.54 a | 34.22 ± 1.69 a | 43.96 ± 1.62 a | 36.67 ± 5.32 a | 47.38 ± 1.87 a |
| Histidine | HIS | 37.54 ± 10.13 | 10.82 ± 10.34 a | 23.19 ± 0.93 a | 26.18 ± 1.75 a | 1.48 ± 0.40 a | 1.53 ± 0.39 a |
| Tyrosine | TYR | 5.47 ± 0.71 | 3.55 ± 1.58 a | 4.00 ± 0.13 | 4.28 ± 0.25 | 0.93 ± 0.36 a | 4.35 ± 0.13 |
| Proline-hydroxyproline (dipeptide) | PHP | 1.85 ± 0.40 | 3.14 ± 1.12 a | 0.66 ± 0.15 | 0.89 ± 0.25 | 0.00 ± 0.00 a | 2.59 ± 0.77 |
| Tryptophan | TRP | 0.99 ± 0.30 | 0.65 ± 0.07 a | 0.26 ± 0.07 a | 0.45 ± 0.05 a | 0.07 ± 0.10 a | 0.77 ± 0.09 |
| Cystathionine | CTH | 0.00 ± 0.00 | 0.21 ± 0.01 a | 0.08 ±0.11 | 0.17 ± 0.12 a | 0.00 ± 0.00 | 0.25 ± 0.07 a |
| Cystine | C-C | 0.42 ± 0.20 | 0.34 ± 0.10 | 0.10 ± 0.15 a | 0.37 ± 0.01 | 0.00 ± 0.00 a | 0.21 ± 0.01 |
| Total Amino acids | Total AA | 407.01 ± 47.9 | 301.67 ± 79.03 a | 385.64 ± 25.48 | 380.36 ± 27.09 | 343.81 ± 60.20 | 422.63 ± 28.26 |
a significantly altered amino acids (p < 0.05).
Figure 1Heatmap exhibition of amino acid profiles from bacterial cells harvested at stationary phase from control and treatments samples (1–5). Each column denotes one biological sample; each row denotes one targeted amino acid. The colors represent relative amino acid abundance in each replicate.
Figure 2(a) Cross-validated PLS-DA score plot comparing the amino acid profiles of the clinical strain (red) and the ATCC29213 (green) strains, which shows the separation achieved during growth to the stationary phase. Colored dots represent individual replicates: 38.8% and 16.2% are the scores of Component 1 and Component 2, respectively, in the PLS-DA. (b) VIP plot exhibiting the 15 most important amino acids identified by PLS-DA for the cells grown to the stationary phase. Colored boxes on the right indicate the relative concentration of the corresponding amino acids in the samples. The VIP is the weighted sum of squares of the PLS-DA loading plot, taking the amount of the Y variable explained into account in each dimension.
Figure 3Venn diagram of the altered amino acids in all treatments. (a) Increased amino acids within all experimental groups. Unique increased amino acids were labelled next to each respective treatment (b) Indicates all amino acid that were decreased all treatments. Exclusive decreased amino acids were labelled beside respective treatment.